We conclude that DIMATE is a very promising drug that opens new therapeutic perspectives in myeloid malignancies with putative interest in lymphoid malignancies as this drug is also able to inhibit the anti-apoptotic effect of bcl-2.18 A limitation of our work concerns the LSC definition. Here, BCL2 is linked to myeloid neoplasm.